Market Overview

Rumor: Big Stake In Allergan Acquired By Valeant Supporter Paulson

Related VRX
Exclusive: SunTrust Managing Director Shares Thoughts On Drug Pricing, Impact On Biotech
The Anti-Price Gouging Lead Poisoning Treatment
Biotech Forum Daily Digest: Biotech Slowly Recovering, Analysts Line Up Behind Omeros, Spotlight On Enanta Pharmaceuticals (Seeking Alpha)
Related AGN
Kevin Kelly's Allergan Trade
Exclusive: SunTrust Top Analysts Explain Fatty Liver Diseases, Galmed's Potential In The Space
Gilead NASH Drug 'Active And Promising,' But Lagging Intercept (Investor's Business Daily)

Allergan Inc. (NYSE: AGN) shares bumped up more than 2 percent on a rumor that Hedge fund Paulson & Co. acquiredsix6 million shares.

The report by Reuters said Paulson backs Valeant Pharmaceuticals (NYSE: VRX) in its proxy battle to acquire Allergan and the new stake puts Paulson among Allergan's top holders.

Valeant needs support from 25 percent of Allergan's holders in order to call a special shareholder meeting to vote on its $53 billion bid.

Allergan has called the offer "grossly inadequate."

With a current market capitalization of about $50.3 billion, Allergan traded recently at $69.02, up 2.2 percent.

Posted-In: News Rumors


Related Articles (AGN + VRX)

View Comments and Join the Discussion!